Direct Renin Inhibition Effects on Atherosclerotic Biomarkers
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The investigators aim to assess if a new blood pressure medication, aliskiren, reduces
various biomarkers of heart disease found in the blood in patients with a history of both
heart disease and type 2 diabetes. The primary hypothesis is that aliskiren will reduce these
biomarkers compared to a calcium channel blocker.